September 14, 2021

Exact Sciences and NSABP Foundation Announce Clinical Validation Study to Detect Minimal Residual Disease in Colorectal Cancer Patients

CORRECT-MRD II study intended to validate the ability of Exact Sciences’ circulating tumor DNA (ctDNA) test to detect minimal residual disease (MRD) and predict cancer recurrence. Fight CRC to help inform study design and support recruitment of patients from different racial, ethnic, and underserved populations. Click here to read the Press Release.

August 17, 2021

Outstanding NSABP Foundation / NRG Oncology Researcher to Receive 2021 PA Breast Cancer Coalition Potamkin Prize

NSABP Foundation and NRG Oncology Breast Cancer Researcher Sandra Swain, MD, FACP, FASCO will be awarded the 2021 Potamkin Prize as announced by NRG Patient Advocate Committee Co-Chair and President of the PA Breast Cancer Coalition Pat Halpin-Murphy. Dr. Swain is a world-renowned researcher and oncologist at Georgetown University Medical Center who currently serves as Co-Chair of the Early Breast Cancer Trialists Collaborative Group (EBCTCG) at Oxford University and as Vice Chair of the NSABP Foundation.

“I cannot think of a more deserving recipient of this award than Dr. Swain,” said Halpin-Murphy. “Her accomplishments, including the groundbreaking CLEOPATRA trial on HER2 positive metastatic breast cancer, have changed the standard of breast cancer care. We are honored to welcome Dr. Swain and to learn about her latest research.”

The first recipient of the Potamkin Prize was Dr. Bernie Fisher whose discoveries transformed standard practice for breast cancer patients. Dr. Swain will receive the award Friday, October 15 during the PA Breast Cancer Coalition Virtual Conference. To hear Dr. Swain’s Opening Session presentation on HER2 positive metastatic breast cancer, visit pbcc.me/conference to register.

July 13, 2021

During the 2021 ASCO Virtual Meeting, Dr. Priya Rastogi, NSABP Foundation medical director, discusses results from the NRG Oncology/NSABP B-42 trial, which evaluated the utility of the 70-gene MammaPrint assay in predicting the benefit of extended letrozole therapy in patients who had completed 5 years of adjuvant endocrine therapy (Abstract 502). Click here to view the video.

Read more

January 19, 2021

The PALLAS primary manuscript has been released online at Lancet Oncology. PALLAS: Palbociclib with adjuvant endocrine therapy in early breast cancer: interim analysis of a multicentre, open-label, randomised, phase 3 study.

Read more

December 9, 2020

Dr. Priya Rastogi presented positive primary outcome data from the NSABP B-58/monarchE trial on the role of abemaciclib in early stage, high risk breast cancer during the San Antonio Breast Cancer Annual Meeting that was held virtually December 8-11, 2020. Press releases have been issued from Eli Lilly and Company, and SABCS/AACR

Read more

December 2, 2020

2020 SABCS Meeting

The San Antonio Breast Cancer Symposium Annual Meeting is being held virtually December 8-11, 2020. A schedule of presentations by NSABP Foundation is available below.

Read more

November 6, 2020

NSABP B-60 activates! DS8201-A-U305 (Destiny – Breast05; NSABP B60)

Effective November 5, 2020, the NSABP B-60 study has been activated and enrollment may begin once all activation requirements are met. Click below to read the press release from Daiichi-Sanko.

Read more

November 5, 2020

Dr. Wolmark is featured speaker at FDA Oncology Center of Excellence lecture series

Norman Wolmark, MD, Chairman of the NSABP Foundation and Group Chair for NRG Oncology, was the speaker at the FDA Oncology Center of Excellence “Icons in Oncology” during their “Icons in Oncology” lecture series that was held virtually on November 2, 2020, for FDA staff. Dr. Wolmark’s lecture was titled “The Contribution of NSABP Clinical Trials to the Management of Early Breast Cancer: an Odyssey.”

October 5, 2020

Dr. Wolmark receives 2020 PNC Elsie Hillman Distinguished Scholar Award

Norman Wolmark, MD, Chairman of the NSABP Foundation and of the NCTN group NRG Oncology, was honored with the PNC Elsie Hillman Distinguished Scholar Award during the UPMC Hillman Cancer Center’s Celebration of Hope virtual event held September 17, 2020. The PNC Elsie Hillman Distinguished Scholar Award was established in 2011 by PNC and is presented to exceptional cancer researcher(s) during UPMC Hillman Cancer Center’s Annual Gala. This year’s Gala was held virtually in response to the COVID-19 pandemic.  For more information about this year’s Gala and Dr. Wolmark’s award, click below to view the event program.

Read more

September 25, 2020

MonarchE/NSABP B-58 results reported at ESMO Virtual Meeting

Positive study results were recently presented for the MonarchE/NSABP B-58 study, sponsored by Eli Lilly, at the European Society for Medical Oncology (ESMO) 2020 Virtual Congress. This study showed that adding the drug abemaciclib to adjuvant endocrine therapy significantly reduced the risk of recurrence for women with high-risk, early-stage breast cancer, an important development for this patient population. NSABP Foundation Medical Director, Priya Rastogi, MD, was a senior investigator for the trial and a senior author for the published results in the Journal of Clinical Oncology. Click below to read the press release.

Read more

July 30, 2020

André Robidoux, MD, long-time researcher with the NSABP and NRG Oncology, dies in MontrealClick below to read the announcement.

Read more

June 24, 2020

Joan B. Goldberg, MPH, approaches retirement from NRG Oncology and the NSABP Foundation. Click below to read the announcement.

Read more

June 16, 2020

MonarchE/NSABP B-58 trial meets primary endpoint with Abemaciclib combo in HR+, HER2- breast cancer. Click below to read the press release from Eli Lilly.

Read more

May 29, 2020

Update on PALLAS, an International Academic Breast Cancer Study Evaluating Adjuvant Palbociclib. Click below to read the press release.

Read more

February 7, 2020

In memorium – Janet Wolter-Grip, MD

It is with much sadness that we convey the passing of Janet Wolter-Grip, MD, on February 4, 2020, at the age of 93. Dr. Wolter was an oncologist and Professor of Medicine at Rush University Medical Center in Chicago. She was a member of ECOG, as well as the legacy NSABP, serving on executive committees for both cooperative groups.  NSABP awarded her the Investigator Lifetime Achievement Award in 2004.  We extend our deepest condolences to her family and colleagues. Click here to read the memorial written by Dr. Wolter’s colleague at Rush University Medical Center, Dr. Melody Cobleigh.

Read more